Treace Medical Concepts, Inc. filings document the regulatory disclosures of a medical technology company focused on devices for bunion and related midfoot surgery. Its 8-K reports cover operating results, preliminary unaudited financial information, Regulation FD investor materials, press-release exhibits and Inline XBRL cover data.
The company’s SEC record also includes disclosures on material financing arrangements, including term loan and revolving loan agreements, as well as officer departures, board changes and committee matters. Proxy materials address annual meeting procedures, director elections, executive compensation, equity awards and corporate governance for the Delaware corporation.
Treace Medical Concepts reported that it has released certain preliminary unaudited financial results for the quarter and year ended December 31, 2025. These results are shared through a press release furnished as an exhibit and are not treated as formally filed financial statements. The company also posted an updated investor presentation on its investor relations website.
Treace plans to use this presentation in meetings with analysts and investors, including at the J.P. Morgan Healthcare Conference on January 14, 2026 at 7:30 a.m. Pacific Time / 10:30 a.m. Eastern Time. A live webcast of this event, along with an archived recording and the presentation, will be available in the Investors section of the company’s website.
Treace Medical Concepts entered into new 60‑month credit facilities consisting of a term loan agreement with SLR Investment Corp. providing up to $125 million across four tranches and a revolving loan agreement with SLR Healthcare ABL providing a $30 million revolver, with potential increases to a total commitment of $50 million. The company drew $60 million at closing under the first term loan tranche. The term loan bears interest at 1‑Month SOFR plus 5.05%, while the revolver bears interest at 3‑Month SOFR plus 4.00%, with additional fees tied to servicing, unused capacity and early repayment.
The loans are secured by substantially all company assets and include a minimum liquidity requirement under which cash and cash equivalents in controlled accounts must exceed 60% of term loans outstanding, with revenue covenants applying if that test is not met. Treace used proceeds from the new term loan to repay and terminate its prior MidCap term and revolving credit agreements, paying $2.3 million in prepayment and exit fees. The new covenants limit the company’s ability to pay cash dividends unless financial conditions in the loan agreements are satisfied. The board also appointed long‑time director John K. Bakewell as lead independent director.
Treace Medical Concepts (TMCI) reported Q3 2025 results. Revenue was $50.2 million, up 11.4% year over year, as more bunion procedure kits were sold, partly offset by lower average selling prices on newer systems. Gross profit was $39.7 million. Operating expenses were $55.4 million, leading to a net loss of $16.3 million, or $0.26 per share.
For the first nine months of 2025, revenue reached $150.2 million and net loss was $49.6 million, or $0.79 per share. As of September 30, 2025, cash and cash equivalents were $7.7 million and marketable securities were $49.7 million. Total principal outstanding under the term and revolving loans was $54.0 million. Stockholders’ equity was $89.2 million. Shares outstanding were 63,718,073 as of October 31, 2025.
Management noted continued adoption of minimally invasive osteotomy solutions and competitive pressures, which have reduced average selling prices even as kit volumes increased.
Treace Medical Concepts (TMCI) furnished its Q3 2025 results via a press release attached as Exhibit 99.1. The information under Item 2.02 is furnished and not deemed filed under the Exchange Act.
The company also announced a board change. Richard W. Mott retired from the Board on November 3, 2025, for personal reasons and not due to any disagreement. On November 5, 2025, the Board reduced its size from eight to seven members; there are currently no vacancies.
Treace Medical Concepts (TMCI) reported an insider transaction on a Form 4. On 10/24/2025, the Chief Innovation Officer recorded a transaction in Common Stock with code F for 208 shares at $0, marked as a disposition. Following the transaction, the officer beneficially owns 373,599 shares, which includes 283,948 restricted stock units. Ownership is reported as direct.
Treace Medical Concepts (TMCI) reported an insider Form 4 for its Chief Legal & Compliance Officer and Corporate Secretary. On 10/25/2025, the filer disposed of 984 shares of common stock at $0 under transaction code F. Following the transaction, the filer beneficially owned 548,281 shares directly. A footnote states this figure includes 426,170 restricted stock units.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 6,260,000 shares of Treace Medical Concepts, Inc., representing 9.91% of the outstanding common stock based on 63,173,126 shares outstanding as of July 31, 2025. The reported position is held directly by Armistice Capital Master Fund Ltd. with Armistice Capital acting as investment manager and Steven Boyd as managing member. The Reporting Persons disclaim sole voting or dispositive power; all voting and dispositive power is reported as shared (6,260,000 shares). The Master Fund is identified as the direct holder and retains rights to dividends or sale proceeds.
Scot Michael Elder, Chief Legal & Compliance Officer and corporate secretary of Treace Medical Concepts (TMCI), reported a Form 4 disclosing an equity transaction dated 08/09/2025. The filing lists a transaction coded "F" involving 10,515 shares at a reported price of $0. After the reported transaction, Mr. Elder beneficially owns 566,149 shares, held directly.
The filing states the beneficial ownership total includes 480,103 restricted stock units and indicates no derivative securities were reported. This disclosure describes the insider's reported change in non-derivative equity holdings and the composition of the reported stake.
Mark Hair, Chief Financial Officer of Treace Medical Concepts (TMCI), reported a change in beneficial ownership of common stock on 08/09/2025. The Form 4 records a disposition of 22,212 shares with a transaction code labeled "F" and a reported transaction price of $0. After the reported transaction the filing shows Mr. Hair beneficially owns 518,964 shares directly; that total expressly includes 421,228 restricted stock units. The filing discloses the magnitude of the ownership change but does not provide explanation for the transaction code or the zero price.
Sean F. Scanlan, identified as Chief Innovation Officer of Treace Medical Concepts, Inc. (TMCI), reported a common stock transaction dated 08/09/2025 on a Form 4. The filing records a transaction coded F and shows the reporting line items 9,814 with a marker D and a post-transaction beneficial ownership total of 373,807 shares held directly.
The form includes an explanatory footnote that the beneficial ownership figure includes 284,798 restricted stock units. The filing was executed by an attorney-in-fact on behalf of Mr. Scanlan as indicated on the form.